Cryo-Cell InternationalSTU:ZCY +5.88%58 FCF Yield % is 18.37 as of Jul. 05, 2026, which is 120% above its 10-year median of 8.35. GuruFocus rates STU:ZCY with a GF Score™ of 58/100 and a GF Value™ of €4.92 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 681 Healthcare Providers & Services companies, Cryo-Cell International ranks better than 90.9% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Cryo-Cell International's FCF Yield % or its related term are showing as below:
STU:ZCY'
s FCF Yield % Range Over the Past 10 Years
Min: -26.36 Med: 8.35 Max: 21.15
Current: 18.37
During the past 13 years, the highest FCF Yield % of Cryo-Cell International was 21.15%. The lowest was -26.36%. And the median was 8.35%.
STU:ZCY's FCF Yield % is ranked better than 90.9% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 1.83
vs STU:ZCY: 18.37
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Cryo-Cell International FCF Yield % Related Terms
Cryo-Cell International FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ZCY vs CCM, CDIX, EHSI: FCF Yield % Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International FCF Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (STU:ZCY) has a FCF Yield % of 18.37 as of Jul. 05, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cryo-Cell International and its competitors. This is 120% above median its historical median of 8.35. According to the industry distribution chart, Cryo-Cell International ranks #62 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 9.1%.
Is Cryo-Cell International's FCF Yield % too high?
Cryo-Cell International's current FCF Yield % of 18.37 is 120% above median its 10-year median of 8.35. The Healthcare Providers & Services industry median FCF Yield % is 1.83. Cryo-Cell International's value of 18.37 is 903.8% above this industry median. Based on the distribution chart, Cryo-Cell International ranks #62 out of 681 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's FCF Yield % compare to CCM and CDIX?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #62 out of 681 companies for FCF Yield %. This places Cryo-Cell International in the top 9% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 1.83. Cryo-Cell International's value of 18.37 is 903.8% above this benchmark. While the company's 10-year median is 8.35 vs. the industry median of 1.83, Cryo-Cell International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Healthcare Providers & Services company?
The median FCF Yield % among Healthcare Providers & Services companies is 1.83, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current FCF Yield % of 18.37 is 903.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median FCF Yield % is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current FCF Yield % is 18.37, which is 120% above median its own 10-year median of 8.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (STU:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.92, compared to a current price of €2.88 — trading 41.5% below its estimated fair value. The current FCF Yield % is 18.37, which is 120% above median its 10-year median of 8.35 and 903.8% above the Healthcare Providers & Services industry median of 1.83. Cryo-Cell International's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current FCF Yield % is 18.37 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €2.88 is trading 41.5% below its estimated GF Value™ of €4.92.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for STU:ZCY:
FCF Yield %: 18.37 (120% above median its 10-year median of 8.35)
GF Value™: €4.92 vs. price of €2.88 (41.5% below fair value)
Industry Position: 903.8% above the Healthcare Providers & Services median (#62 of 681)
No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for STU:ZCY
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZCY has been successfully added to your 
